A B S T R A C T The serum bactericidal activity (SBA) of cirrhotic patients was compared with that of normal individuals using the release of 51Cr from radiolabeled Escherichia coli as the assay method. 80% (22/27 ) of patients were found to have deficient SBA against at least one of three smooth, serum-sensitive test strains ofE. coli. Cirrhotic patients were found to have normal levels of serum lysozyme. Although some patients were mildly hypocomplementemic, this abnormality did not correlate with the presence of a bactericidal defect. Bactericidal antibody in normal and cirrhotics' sera was limited to the immunoglobulin (Ig)M class. Purified IgM from patients with deficient SBA against E. coli 0111 had lower concentrations of bactericidal antibody for that E. coli than did IgM from normal sera; the calculated bactericidal activity oftotal serum IgM was also lower. The bactericidal defect in cirrhotic serum could be completely corrected by either human antiserum to the homologous strain of E. coli or by purified, normal human IgM. However, because higher concentrations of IgM were required to restore normal SBA to a cirrhotic's serum than to agammaglobulinemic serum, there may be an inhibitor of bactericidal antibody in addition to a deficiency of bactericidal IgM antibody to E. coli in the serum of patients with cirrhosis. The bactericidal activity of the alternative complement pathway was also assessed. Sera from cirrhotic patients had no deficit in SBA attributable to the alternative complement pathway. In fact, in some, the activity of the alternative complement pathway was supernormal, compensating in part for the deficit in IgMmediated SBA.
INTRODUCTION
Patients with Laennec's cirrhosis are unusually susceptible to infections with Gram-negative bacilli: the syndromes of spontaneous peritonitis and spontaneous colon bacillus bacteremia are commonly associated with this disease (1) (2) (3) (4) . The high incidence of infection with both commensal and uncommonly isolated Gramnegative bacteria (5, 6) suggests that patients with cirrhosis have abnormalities in their host defenses against Gram-negative bacteria. Although the presence of ascites itself may contribute to the high incidence of peritonitis and bacteremia, the high frequency of infections at other sites in patients with Laennec's cirrhosis suggests a more general abnormality in host defenses. Defective chemotaxis because of a circulating inhibitor is, to date, the only such abnormality of host defenses that has been documented (7) . In the presence ofcirrhosis, clearance of radioactive particles by the liver is abnormal (8) , but it has not been shown that the clearance of bacteria is similarly depressed.
Normal serum is bactericidal for a wide variety of Gram-negative bacteria (9) ; normal bactericidal activity may be an important host defense against tissue invasion and septicemia (10) . However, serum bactericidal activity has not been systematically studied in patients with cirrhosis. In this paper we report that the majority ofpatients with severe cirrhosis have diminished serum bactericidal activity against Escherichia coli. This abnormality is associated with decreased immunoglobulin (Ig)M bactericidal activity and not with deficiencies of complement of lysozyme. vanced liver disease. All patients had ascites and(or) pedal edema. None of the patients had received blood transfusions in the month before the study, and none was infected or receiving systemic antibiotics. The diagnosis of Laennec's cirrhosis was confirmed by biopsy or autopsy in 50% of the patients. One patient had biliary cirrhosis. The majority of the patients had evidence of diminished hepatic protein synthesis, such as hypoalbuminemia and prolonged prothrombin time.
Hyperglobulinemia, which is characteristic of this disease, was found in one-half of the patients. Many also had hyperbilirubinemia.
Control serum was obtained from healthy volunteers who were in their third or fourth decade of life. Sera from 10 individuals were combined to make a serum pool. Serum from patients and the control serum pool were frozen at -70°in 1-ml aliquots.
Bacteria. E. coli 0111:B4 is a smooth, serum-sensitive, laboratory strain. E. coli 06 was isolated from the urine of a patient with pyelonephritis, and E. coli 04 was isolated from the blood of a patient with Laennec's cirrhosis. Both of the clinical isolates are smooth, serum-sensitive, motile organisms. Their K and H antigens have not been characterized. All bacteria were stored in trypticase soy broth at -700.
Bactericidal assay. Bactericidal activity was determined by measuring the release of 5'Cr from bacteria as previously described (11) . For each experiment, 1 ml of the frozen stock was added to 10 ml of trypticase soy broth and grown overnight at 37°C. 0.1 ml of the overnight growth was subcultured into 50 ml of trypticase soy broth and incubated in a shaking water bath at 37°C for 150 min before labeling with 5'Cr. The exponentially growing bacteria were then labeled with 150 ,uCi 5'Cr (as sodium chromate, Amersham Corp., Arlington Heights, Ill.) for 45 min at 370C, washed free of unbound radioactivity with cold, 0.1 M phosphate-buffered saline (PBS),' pH 7.4, and then resuspended in PBS at a concentration of 2-5 x 10' colony-forming units per milliliter. The serum to be tested was mixed with the bactericidal suspension in a ratio of 9:1 (vol/vol) and incubated at 370C. Aliquots were removed at intervals and filtered through 0.45-micron filters (HAWP, Millipore Corp., Bedford, Mass.). As a control for nonspecific release of 5'Cr, labeled bacteria were suspended in PBS and processed as above. Radioactivity in the filtrates and in the unfiltered sera was measured in an automatic gamma counter (Nuclear-Chicago, Des Plaines, Ill.). The amount of 5'Cr specifically liberated by serum nwas expressed as a percentage ofthe total radioactivity in the serum after subtracting radioactivity released spontaneously by bacteria incubated in PBS. %5'Cr release = (cpm serum filtrate -cpm PBS filtrate/ cpm unfiltered serum -cpm PBS filtrate) x 100.
Chromate release was compared with a standard bactericidal assay in several experiments. The radiolabeled bacteria were removed from serum at zero time and at intervals thereafter. Each aliquot was serially diluted in sterile saline, and the appropriate dilutions were spread, in duplicate, over the surface of the trypticase soy agar culture plates which were then incubated overnight. Colonies were counted, and the number of surviving colony-forming units (CFU) was determined.
Anttibody. Antiserum toE. coli 0111 with a hemagglutinating (HA) titer of 1:4,000, prepared by hyperimmunizing human volunteers vith boiled bacteria, was kindly provided by Dr. Elizabeth Zeigler, University of California, San Diego 'Abbreviations used in this paper: CFU, colony-forming units; HA, hemagglutinating; PBS, phosphate-buffered saline; SBA, serum bactericidal activity. (12) . Antiserum to E. coli 04 (HA titer, 1:2,000) was prepared by injecting rabbits intravenously with boiled bacteria every other day for 2 wk. Animals were bled to obtain serum 1 wk after the last injection.
Complement. Total hemolytic complement was measured by the method of Kent and Fife (13) . Concentrations of C3 and C4 were measured by radial immunodiffusion (14) with reagents purchased from Hyland Diagnostics Div., Travenol Laboratories, Costa Mesa, Calif. C3PA (factor B) concentrations were measured similarly with reagents purchased from Calbiochem-Behring Corp., San Diego, Calif.
Serum from a patient (J.L.) with acquired common variable hypogammaglobulinemia was used as the complement source for 5'Cr-release studies. This serum had the following characteristics: no measurable isohemagglutinins; IgG and IgM concentrations of <50 mg/dl and <5 mg/dl, respectively; normal total hemolytic complement activity; and normal C3, C4, and factor B concentrations. Neither diluted guinea pig serum nor diluted rabbit serum were adequate complement sources for the 5'Cr release assay.
Immunoglobulin separation. Lipoproteins were precipitated from serum with dextran sulfate (500,000 mol wt) (15) . The supernate was dialyzed against a 0.1-M Tris buffer (pH 7.5); and 8 ml was added to a 2.5 x 100-cm column of Bio-Gel A-5M (Bio-Rad Laboratories, Richmond, Calif.). The protein was eluted with Tris buffer in 0.15 M NaCl at 30 ml/h. The effluent was monitored continuously at a wavelength of 280 nm. Individual protein peaks were pooled and concentrated with an ultrafiltration cell (Amicon Corp., Lexington, Mass.). The IgM in the first peak was further purified and separated from the dextran sulfate by use of concanavalin A Sepharose (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.) (16) . IgG from the second peak was separated from contaminating IgA by use of DEAE-Sephadex (Phannacia Fine Chemicals) (17) . The concentrations of IgA, IgG, and IgM in each of the purified fractions were determined by radial immunodiffusion. The IgM fractions were free of measurable IgG, and vice versa. IgM fractions did contain IgA in approximately equal concentrations.
1gM bactericidal activity. The separated IgM fractions were serially diluted in Dulbecco's buffered saline (18) containing 1% bovine serum albumin, and 0.1-ml aliquots added to an equal volume (0.1 ml) of complement in 12 x 75-mm glass tubes. 5'Cr-labeled E. coli 0111 (0.5 x 106 organisms in 0.02 ml of PBS) were added and the tubes incubated stationary at 36°C for 20 min. The percentage of 5'Cr release was determined as usual and compared with a maximum 5'Cr release (5'Cr release by pooled, normal human serum). A unit of IgM bactericidal activity is defined as the amount which induces 50% of maximum 5'Cr release. The reciprocal of the concentration of the IgM determined to contain one bactericidal unit per milliliter is a measure of the concentration of specific bactericidal antibody in that IgM fraction. That value (units per microgram IgM), multiplied by the concentration of IgM present in the starting serum, gives the total serum IgM bactericidal activity.
Hemagglitination titer. Human 0 erythrocytes were sensitized with alkali-treated lipopolysaccharide which was extracted from E. coli 0111 by the method of Westphal et al. (19) . 25 Al of a heat-inactivated serum was serially diluted in microdilution trays (25 IAI/well), and 25 ,ul of a 1% suspension of sensitized erythrocytes was added to each well. The mixture was incubated at 37°C for 2 h and then held overnight at 40C.
Hemagglutination was then read macroscopically. All HA activity was eliminated when serum was treated with 2-mercaptoethanol, indicating that the HA antibody was IgM (20) .
RESULTS
We compared the kinetics of 51Cr release from E. coli 0111 with the kinetics of bacterial killing (as measured by change in CFU) in both normal and cirrhotic sera. As shown in Fig. 1 , release of 51Cr paralleled bacterial killing in both sera. In the normal serum, maximum 51Cr release from E. coli 0111 was achieved after 7 min, by which time >95% of the inoculum had been killed. In the cirrhotics' serum, the rates of 5'Cr release and bacterial killing were both decreased compared with normal serum. Nevertheless, 5tCr release paralleled bacterial killing. For each of the three test strains of E. coli, we compared bacterial killing with 51Cr release by normal (pooled) serum and serum from a patient with cirrhosis. In every instance, normal 5tCr release was indicative of normal bactericidal activity and decreased 5'Cr release reflected diminished bactericidal activity. We therefore used 51Cr release as our assay method to compare the bactericidal activity of different sera.
We measured the capacity of normal and cirrhotics' sera to release 51Cr from three serotypes of E. coli. Normal 5'Cr release for each microorganism was defined as +2 SD from the mean of 5tCr release by neat, normal sera. As illustrated in Fig. 2 , the percentage of 5'Cr released from E. coli 0111 was below normal in 44% (12/27) of the cirrhotics' sera; from E. coli 06, in 36% (9/25); and from E. coli 04, in 61% (8/13 ). All sera were tested against E. coli 0111 but, because we had limited quantities of sera from some patients, not all were tested against the other two serotypes ofE. coli. FIGURE 1 51Cr release and surviving CFU were determined at timed intervals after 51Cr-labeled E. coli 0111 were added to a normal serum and to serum from a cirrhotic patient, 0.1 ml of saline containing 5 x 107 CFU was added to 0.9 ml of neat serum.
The kinetics of 51Cr release by sera obtained from normal volunteers and from patients with cirrhosis were also compared. Four representative sera from cirrhotic patients are compared with normal serum (pooled) in Fig. 3 . There is very little variation in the rate of 5tCr release by normal serum, and the activity of the pooled serum was representative of 51Cr release by individual normal sera (11) . While 51Cr release from E. coli 0111 was accomplished rapidly by the normal serum, reaching a plateau within 10 min, the rate of 51Cr release by the cirrhotics' sera was so slow that after 20 min the percentage of 51Cr released was still significantly less than that released by normal serum. In fact, 51Cr release by two of the four sera did not achieve control values even after 60 min. In sera with less pronounced defects, 51Cr release reached control values after 15-20 min.
To determine whether this decreased rate of 51Cr release was a result of a low molecular weight inhibitor, serum was dialyzed overnight in Dulbecco's buffered saline at 4°C. After dialysis, there was a slight decrease in 51Cr release by both the normal and the patients' serum, probably because of some loss of complement activity (Fig. 4) . Significantly, there was no increase in the bactericidal activity of a cirrhotics' serum after dialysis, suggestive that the abnormality was not a result of a dialyzable inhibitor.
Sera from cirrhotic patients and normal serum were mixed together in varying proportions to test for the presence ofan inhibitor in the cirrhotics' sera ( Table I) . As much as 0.5 ml of cirrhotics' sera did not inhibit 51Cr release by 0.4 ml normal serum. Furthermore, preincubation of bacteria with cirrhotics' sera did not prevent the subsequent release of 5tCr when the preincubated bacteria were washed and then resuspended in normal serum (Table II) .
After failing to demonstrate an inhibitor, we examined the functional activity ofeach ofthe known components of the serum bactericidal system. Serum lysozyme was measured spectrophotometrically with Micrococcuslysodeikticus as the substrate (21) and crystalline egg white lysozyme (Sigma Chemical Co., St. Louis, Mo.) as the standard. Serum lysozyme values ranged from 6 to 31 U/ml in patients with Laennec's cirrhosis (Table  III) . The normal range was 6-12 U/ml. No cirrhotic patient had a low level of serum lysozyme and one-half of those tested had concentrations which were higher than normal.
Total hemolytic complement activity was measured in sera from 16 cirrhotic patients. Immunoreactive C3, C4, and factor B (C3PA) concentrations were also measured in most of these sera. As shown in Table III than the Mg-EGTA-resistant activity of the normal serum. WithE. coli 04, we compared the effect of 10mM Mg-EGTA on 5'Cr release by normal and cirrhotics' sera. Bacteria were incubated in sera for 30 min. The addition of Mg-EGTA decreased the percentage of 5tCr released by 7 of 9 normal sera, but only 2 of 11 sera from cirrhotics showed a measurable decrease in 55Cr release (data not shown). This is further evidence that nearly all of the SBA against E. coli of most patients with cirrhosis is a result of the activity of the alternative complement pathway. We compared the bactericidal activity of 28 sera from cirrhotic patients for two serotypes ofE. coli (Table IV) . In 12 of 28 instances there were discordant results: 12 sera had decreased bactericidal activity against either E. coli 0111 or E. coli 06, but not both. This suggested that the bactericidal defect in these patients had antigenic specificity which varied from serum to serum. To further examine this possibility, we measured the bactericidal titers of antibodies isolated from abnormal sera. Normal and cirrhotics' sera were fractionated to separate IgG and IgM as described in Methods. Each fraction was concentrated so that the concentration of the immunoglobulin was equal to that in the starting serum. The bactericidal antibody titer of the IgG and IgM from all of the fractionated sera was measured with E. coli 0111. When added to complement, there was no release of 51Cr by IgG from any serum except hyperimmune serum. All of the bactericidal antibody activity in both normal and cirrhotics' sera was found in the IgM fraction. Fig. 6 illustrates the relationship of IgM concentration to 5tCr release for purified IgM from two normal sera and one cirrhotic's serum. The concentration of IgM which induced 50% of normal 51Cr release was determined by interpolation. This value was used to determine the bactericidal activity of the purified IgM (units per microgram) and to determine the total serum IgM bactericidal activity (units per milliliter of serum). These values for four cirrhotics' and four normal sera are shown in Table V , where they are compared with the bactericidal activity and the HA titers of the corresponding whole sera. In the cirrhotics' sera, serum bactericidal activity was proportional to both the bactericidal activity of purified IgM and the total serum IgM bactericidal activity. All four normal sera had essentially identical serum bactericidal activity, even though total serum IgM bactericidal activity ranged from 10.5 to 129.5 U/ml. Apparently, all of these values were above the threshold of specific bactericidal IgM activity needed for maximum 5'Cr release from E. coli 0111. Total IgM bactericidal activity was roughly correlated with HA titer, at least at the extremes. However, HA titers did not discriminate between sera with normal and decreased SBA as well as did the IgM bactericidal titers.
Because we had found that cirrhotics' sera were de- These results suggest that, in addition to the deficiency in bactericidal IgM, there may also be a "blocking" factor in cirrhotic sera, such as noncomplement-fixing antibody (24) . Further work is needed to clarify this point.
DISCUSSION
In this study we found that most patients with advanced cirrhosis of the liver had diminished SBA against at least one of the three test strains of E. coli. This abnormality was manifest primarily as a kinetic defect, i.e., E. coli were killed more slowly in cirrhotic than in normal serum. At its extreme, the bactericidal reaction was so slow that the cirrhotics' sera essentially lacked bactericidal activity. 80% (22/27) had diminished bactericidal activity against at least one of the three E. coli strains (Fig. 2) . We consider 80% to be a minimal estimate of the prevalence of the bactericidal defect in cirrhosis because we used only three test strains of E. coli and it was not unusual for a serum to have decreased SBA against only one strain. Had we used more strains, we might have identified a bactericidal defect in all patients with cirrhosis. Because all sera were tested undiluted, we believe that these in vitro measurements of SBA are true estimates of in vivo bactericidal capacity. The measurement of SBA was facilitated by the use of the 5'Cr-release assay. We have found that with each strain of E. coli, the percentage of 5'Cr released after exposure to human serum is proportional to bacterial killing as measured by decrease in CFU. We have pre- and that 51Cr release is therefore a useful method for studying the kinetics of the bactericidal reaction (11) . The ease with which serial measurements of 51Cr release can be made allowed us to compare the initial rates of bactericidal reactions in serum from cirrhotic and normal individuals (Fig. 3) . This is quite difficult to do with viability assays. Furthermore, the use of 51Cr release made it practical to measure the SBA of serum from large numbers ofcirrhotic patients using three different strains of E. coli. The abnormality of SBA observed in cirrhotics' sera might have been a result ofan abnormality ofantibody, complement, or lysozyme. We found that patients with 14 cirrhosis had a normal or increased activity oflysozyme, but some were hypocomplementemic, as has been reported (7) . In our patients, the complement abnormalities were quite mild and were not well correlated with deficiencies in SBA. We therefore sought to measure bactericidal antibody in these patients. Antibody-mediated humoral defense mechanisms have not been studied previously in patients with cir-30 rhosis, perhaps because it has been shown that these patients have high titers of agglutinating antibacterial antibodies (25 10 5 IgM (jg/mI) FIGURE 6 IgM was purified as described in Methods. 0.1 ml of saline was serially diluted in Dulbecco's buffered saline plus 1% bovine serum albumin, and 0.1 ml of human complement was added to each dilution. Radiolabeled E. coli 0111 (final concentration 2.5 x 107 ml) were added, and the tubes were incubated at 37°C for 20 min. The percentage of 5'Cr released by pooled, normal serum was used as the 100% standard, and percentage of 5'Cr release induced by the IgM was compared with that value. There was no specific release of 51Cr by the IgM fractions in the absence of complement. IgM concentrations were determined by radial immunodiffusion. This figure illustrates the bactericidal activity of IgM from two normal sera (solid lines) and a cirrhotic's serum (dashed line). (31) . We did attempt to quantitate anti-E. coli antibody in each immunoglobulin class using indirect immunofluorescence with an antibody specific for each human Ig heavy chain (Meloy Laboratories, Inc., Springfield, Va.), but the technique was too insensitive. All sera, both normal and cirrhotic, had titers between 0 and 1:4.
In view ofthe deficiency in bactericidal antibody observed in cirrhotic patients, it was ofinterest to examine the functional activity of their alternative complement pathway, which does not use IgM antibody (32) . We tested alternative pathway function by chelating Ca++ with Mg-EGTA (21), which slows the bactericidal reaction in normal serum. However, Mg-EGTA did not have that effect on the bactericidal activity of sera from many cirrhotics. In many cirrhotics' sera, such as the one shown in Fig. 5 , the SBA of chelated serum and neat serum was nearly identical. Thus, whereas most of the SBA of normal serum is a result of the activity of the classical C pathway, the SBA of many cirrhotic sera is a result of the activity of the alternative C pathway. Furthermore, their alternative C pathway is sometimes sufficiently active to produce normal SBA.
The exact role that serum bactericidal activity plays in immunity to Gram-negative infections is controversial. It has been shown that acquired immunity to Haemophilus influenzae (33) and to Neisseria meningitidis (34) correlates with the development of bactericidal antibody. Although normal adults have a high degree of "natural" immunity to E. coli and normal serum contains "natural" antibody that is bactericidal for many strains of E. coli (and other Gram-negative bacilli), the relationship between immunity to these Gram-negative bacilli and SBA has not been conclusively established. However, because most strains of E. coli isolated from the blood of bacteremic patients are serum resistant (10), whereas many fecal strains are serum sensitive, it is likely that SBA does play a role in natural immunity.
The importance of SBA has been demonstrated in experimental models. Durack and Beeson (35) have shown that the serum resistance of the bacteria and the host SBA can both influence the outcome of an E. coli infection. In their experiments, rabbits with congenital C6 deficiency developed endocarditis after intravenous injections of either serum-sensitive or serum-resistant E. coli. Normal rabbits were resistant to infection with the serum-sensitive, but not the serum-resistant, E. coli. Similar results have recently been obtained with a model of E. coli meningitis (36) . Because C6-deficient rabbits completely lack SBA but have normal opsonic capacity, these studies support the importance of SBA as a natural defense mechanism. Cirrhosis may be a disease which mimics these experimental models. Under normal circumstances, E. coli remain within the intestinal lumen and are not pathogenic. In the presence ofportal hypertension, bacteria which are ordinarily "noninvasive" may pass out of the intestinal lumen and gain access to the circulation; this would be analogous to the direct injection ofthe bacteria in the experimental animal. These bacteria are more likely to multiply in the circulation if they are fully resistant to SBA or if the bacteria are serum sensitive but the host lacks normal SBA (which we have found to be the case in cirrhotics). In this regard, it is interesting that 3 out of 10 strains ofE. coli isolated from the blood of patients with cirrhosis were very serum sensitive (i.e., they exhibited a 90% decrease in CFU after 20 min in normal serum), whereas 95% of blood-culture isolates from unselected patients are serum resistant (10) .
We have established that there is a deficiency in bactericidal IgM antibody activity against one or more strains of E. coli in patients with advanced cirrhosis. It is possible that this deficiency has other ramifications besides the bactericidal defect; it may also affect cellular defenses. For example, while IgM alone is not opsonic, it becomes opsonic in the presence ofcomplement (37) . The possibility that cirrhotics have an opsonic defect in addition to their bactericidal defect is presently under investigation.
